Singapore, Sept. 18 -- Akeso has received clearance from the Center for Drug Evaluation under China's National Medical Products Administration to initiate a Phase I clinical trial of AK158D1 in patients with advanced malignant solid tumours.

AK158D1 is a next-generation bispecific antibody-drug conjugate targeting both EGFR and TROP2.

The candidate becomes Akeso's fourth ADC to enter clinical development.

It joins a clinical-stage portfolio that includes AK146D1 targeting TROP2 and Nectin-4, AK138D1 targeting HER3 and AK157D1 targeting B7-H3.

AK158D1 is also Akeso's second bispecific ADC to enter clinical development.

The company is advancing a strategy combining next-generation immuno-oncology approaches with new ADC platforms.

EGF...